Borderline Resectable Pancreatic Cancer: Challenges for Clinical Management

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/CAAC.21660
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/CAAC.21590
   PubMed Web of Science ®Google Scholar
• Soweid AM. The borderline resectable and locally advanced pancreatic ductal adenocarcinoma: definition. Endosc Ultrasound. 2017;6(Suppl 3):S76–S78. doi:10.4103/EUS.EUS_66_17
   PubMed Web of Science ®Google Scholar
• Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10(1):10. doi:10.14740/WJON1166
   PubMedGoogle Scholar
• Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1–2):349–361. doi:10.1016/J.CELL.2011.11.025
   PubMed Web of Science ®Google Scholar
• Grossberg AJ, Chu LC, Deig CR, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin. 2020;70(5):375–403. doi:10.3322/CAAC.21626
   PubMed Web of Science ®Google Scholar
• Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(4):439–457. doi:10.6004/JNCCN.2021.0017
   PubMed Web of Science ®Google Scholar
• Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(22):2654–2667. doi:10.1200/JCO.2016.67.5561
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825. doi:10.1056/NEJMOA1011923/SUPPL_FILE/NEJMOA1011923_DISCLOSURES.PDF
   PubMed Web of Science ®Google Scholar
• von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703. doi:10.1056/NEJMoa1304369
   PubMed Web of Science ®Google Scholar
• Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–2406. doi:10.1056/NEJMoa1809775
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, Phase 3 trial. Lancet. 2017;389(10073):1011–1024. doi:10.1016/S0140-6736(16)32409-6
   PubMed Web of Science ®Google Scholar
• Strobel O, Hank T, Hinz U, et al. Pancreatic cancer surgery: the new R-status counts. Ann Surg. 2017;265(3):565–573. doi:10.1097/SLA.0000000000001731
   PubMed Web of Science ®Google Scholar
• Tummala P, Howard T, Agarwal B. Dramatic survival benefit related to R0 resection of pancreatic adenocarcinoma in patients with tumor ≤25 mm in size and ≤1 involved lymph nodes. Clin Transl Gastroenterol. 2013;4(3):e33. doi:10.1038/CTG.2013.4
   PubMed Web of Science ®Google Scholar
• Kang MJ, Jang JY, Chang YR, Kwon W, Jung W, Kim SW. Revisiting the concept of lymph node metastases of pancreatic head cancer: number of metastatic lymph nodes and lymph node ratio according to N stage. Ann Surg Oncol. 2014;21(5):1545–1551. doi:10.1245/S10434-013-3473-9
   PubMed Web of Science ®Google Scholar
• Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13(8):1035–1046. doi:10.1245/ASO.2006.08.011
   PubMed Web of Science ®Google Scholar
• Katz MHG, Marsh R, Herman JM, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20(8):2787–2795. doi:10.1245/S10434-013-2886-9
   PubMed Web of Science ®Google Scholar
• Vauthey JN, Dixon E. AHPBA/SSO/SSAT consensus conference on resectable and borderline resectable pancreatic cancer: rationale and overview of the conference. Ann Surg Oncol. 2009;16(7):1725–1726. doi:10.1245/S10434-009-0409-5
   PubMed Web of Science ®Google Scholar
• Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2–11. doi:10.1016/J.PAN.2017.11.011
   PubMed Web of Science ®Google Scholar
• Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013;20(7):2188–2196. doi:10.1245/S10434-012-2809-1
   PubMed Web of Science ®Google Scholar
• Isaji S, Kishiwada M, Kato H. Surgery for borderline resectable pancreatic cancer: the Japanese experience. In: Multimodality Management of Borderline Resectable Pancreatic Cancer. Springer; 2015:265–287. doi:10.1007/978-3-319-22780-1_17
   Google Scholar
• Tas F, Sen F, Odabas H, Kilic L, Keskin S, Yildiz I. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Int J Clin Oncol. 2013;18(5):839–846. doi:10.1007/S10147-012-0474-9
   PubMed Web of Science ®Google Scholar
• Anger F, Döring A, van Dam J, et al. Impact of Borderline resectability in pancreatic head cancer on patient survival: biology matters according to the new international consensus criteria. Ann Surg Oncol. 2021;28(4):2325–2336. doi:10.1245/s10434-020-09100-6
   PubMed Web of Science ®Google Scholar
• Kato Y, Yamada S, Tashiro M, et al. Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer. HPB. 2019;21(9):1211–1218. doi:10.1016/J.HPB.2019.01.012
   PubMed Web of Science ®Google Scholar
• Hayasaki A, Isaji S, Kishiwada M, et al. Survival analysis in patients with pancreatic ductal adenocarcinoma undergoing chemoradiotherapy followed by surgery according to the international consensus on the 2017 definition of borderline resectable cancer. Cancers. 2018;10(3):65. doi:10.3390/CANCERS10030065
   PubMed Web of Science ®Google Scholar
• Seufferlein T, Bachet JB, van Cutsem E, Rougier P. Pancreatic adenocarcinoma: ESMO–ESDO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2012;23(SUPPL.7):vii33–vii40. doi:10.1093/ANNONC/MDS224
   PubMed Web of Science ®Google Scholar
• Khorana AA, McKernin SE, Berlin J, et al. Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update. J Clin Oncol. 2019;37(23):2082–2088. doi:10.1200/JCO.19.00946
   PubMed Web of Science ®Google Scholar
• van Dam JL, Janssen QP, Besselink MG, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials. Eur J Cancer. 2022;160:140–149. doi:10.1016/j.ejca.2021.10.023
   PubMed Web of Science ®Google Scholar
• Yoo C, Lee SS, Song KB, et al. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a phase 2 study for clinical and biomarker analysis. Br J Cancer. 2020;123(3):362. doi:10.1038/S41416-020-0867-X
   PubMed Web of Science ®Google Scholar
• Kondo N, Uemura K, Sudo T, et al. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact. Eur J Cancer. 2021;159:215–223. doi:10.1016/J.EJCA.2021.10.012
   PubMed Web of Science ®Google Scholar
• Unno M, Motoi F, Matsuyama Y, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05). J Clin Oncol. 2019;37(4_suppl):189. doi:10.1200/JCO.2019.37.4_SUPPL.189
   Web of Science ®Google Scholar
• Ghaneh P, Palmer DH, Cicconi S, et al. ESPAC-5F: four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer. J Clin Oncol. 2020;38(15_suppl):4505. doi:10.1200/JCO.2020.38.15_SUPPL.4505
   Web of Science ®Google Scholar
• Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019;111(8):782. doi:10.1093/JNCI/DJZ073
   PubMedGoogle Scholar
• Janssen QP, van Dam JL, Kivits IG, et al. Added value of radiotherapy following neoadjuvant FOLFIRINOX for resectable and borderline resectable pancreatic cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2021;28(13):8297. doi:10.1245/S10434-021-10276-8
   PubMed Web of Science ®Google Scholar
• Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–1773. doi:10.1200/JCO.19.02274
   PubMed Web of Science ®Google Scholar
• Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;40(11):1220–1230. doi:10.1200/JCO.21.02233
   PubMed Web of Science ®Google Scholar
• Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268(2):215–222. doi:10.1097/SLA.0000000000002705
   PubMed Web of Science ®Google Scholar
• Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(7):963–969. doi:10.1001/JAMAONCOL.2018.0329
   PubMed Web of Science ®Google Scholar
• Ruano-Ravina A, Almazán Ortega R, Guedea F. Intraoperative radiotherapy in pancreatic cancer: a systematic review. Radiother Oncol. 2008;87(3):318–325. doi:10.1016/J.RADONC.2007.12.002
   PubMed Web of Science ®Google Scholar
• Katz MHG, Shi Q, Meyers JP, et al. Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas. J Clin Oncol. 2021;39(3_suppl):377. doi:10.1200/JCO.2021.39.3_SUPPL.377
   Web of Science ®Google Scholar
• Zins M, Matos C, Cassinotto C. Pancreatic adenocarcinoma staging in the era of preoperative chemotherapy and radiation therapy. Radiology. 2018;287(2):374–390. doi:10.1148/RADIOL.2018171670/ASSET/IMAGES/LARGE/RADIOL.2018171670.FIG10F.JPEG
   PubMed Web of Science ®Google Scholar
• Katz MHG, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749–5756. doi:10.1002/CNCR.27636
   PubMed Web of Science ®Google Scholar
• Cassinotto C, Mouries A, Lafourcade JP, et al. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy. Radiology. 2014;273(1):108–116. doi:10.1148/RADIOL.14132914
   PubMed Web of Science ®Google Scholar
• Noda Y, Pisuchpen N, Mercaldo ND, et al. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy. Eur Radiol. 2022;32(4):2470–2480. doi:10.1007/S00330-021-08304-Y/FIGURES/5
   PubMed Web of Science ®Google Scholar
• Lee W, Oh M, Kim JS, et al. Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. Br J Surg. 2021;109(1):61–70. doi:10.1093/BJS/ZNAB229
   PubMed Web of Science ®Google Scholar
• Lee W, Park Y, Kwon JW, et al. Reduced and normalized carbohydrate antigen 19-9 concentrations after neoadjuvant chemotherapy have comparable prognostic performance in patients with borderline resectable and locally advanced pancreatic cancer. J Clin Med. 2020;9(5):1477. doi:10.3390/JCM9051477
   PubMed Web of Science ®Google Scholar
• Murakami M, Fujimori N, Ohno A, et al. Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study. Discov Oncol. 2022;13(1). doi:10.1007/S12672-021-00462-1
   PubMedGoogle Scholar
• Kunzmann V, Siveke JT, Algül H, et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(2):128–138. doi:10.1016/S2468-1253(20)30330-7
   PubMed Web of Science ®Google Scholar
• Ivey GD, Shoucair S, Delitto DJ, et al. Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. World J Surg 2022. doi:10.1007/S00268-022-06667-X
   PubMed Web of Science ®Google Scholar
• Janssen QP, van Dam JL, Bonsing BA, et al. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer. 2021;21(1). doi:10.1186/S12885-021-08031-Z
   Web of Science ®Google Scholar
• Schizas D, Charalampakis N, Kole C, et al. Immunotherapy for pancreatic cancer: a 2020 update. Cancer Treat Rev. 2020;86:102016. doi:10.1016/J.CTRV.2020.102016
   PubMed Web of Science ®Google Scholar
• Kamath SD, Kalyan A, Kircher S, et al. Ipilimumab and gemcitabine for advanced pancreatic cancer: a phase Ib study. Oncologist. 2020;25(5):e808–e815. doi:10.1634/THEONCOLOGIST.2019-0473
   PubMed Web of Science ®Google Scholar
• Hewitt DB, Nissen N, Hatoum H, et al. A phase 3 randomized clinical trial of chemotherapy with or without algenpantucel-L (HyperAcute-pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer. Ann Surg. 2022;275(1):45–53. doi:10.1097/SLA.0000000000004669
   PubMed Web of Science ®Google Scholar
• Douglas JE, Liu S, Ma J, et al. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. BMC Cancer. 2022;22(1):1. doi:10.1186/S12885-021-09095-7
   PubMed Web of Science ®Google Scholar
• James ND, Sydes MR, Clarke NW, et al. STAMPEDE: systemic therapy for advancing or metastatic prostate cancer--a multi-arm multi-stage randomised controlled trial. Clin Oncol. 2008;20(8):577–581. doi:10.1016/J.CLON.2008.07.002
   Web of Science ®Google Scholar
• Cros J, Raffenne J, Couvelard A, Poté N. Tumor heterogeneity in pancreatic adenocarcinoma. Pathobiology. 2018;85(1–2):64–71. doi:10.1159/000477773
   PubMed Web of Science ®Google Scholar
• Rachakonda PS, Bauer AS, Xie H, et al. Somatic mutations in exocrine pancreatic tumors: association with patient survival. PLoS One. 2013;8:4. doi:10.1371/JOURNAL.PONE.0060870
   Web of Science ®Google Scholar
• Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317–327. doi:10.1056/NEJMOA1903387
   PubMed Web of Science ®Google Scholar
• Reddy AV, Cs H, Sehgal S, et al. Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant chemotherapy and stereotactic body radiotherapy followed by surgical resection. Radiat Oncol J. 2021;39(4):304–314. doi:10.3857/ROJ.2021.00815
   PubMed Web of Science ®Google Scholar